利伐沙班联合阿司匹林对慢性冠脉或外周动脉疾病患者的死亡率获益
COMPASS试验随机纳入18,278例慢性冠心病或外周动脉疾病患者,比较利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次与阿司匹林单药治疗。中位随访23个月,联合治疗组全因死亡风险显著降低(HR 0.82,95%CI 0.71-0.96,P=0.01),心血管死亡亦降低(HR 0.78,95%CI 0.64-0.96,P=0.02),非心血管死亡无差异;基线高危特征越多,绝对死亡获益越大。
要点
- 利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次降低全因死亡风险。
- 联合治疗降低心血管死亡,非心血管死亡无显著差异。
- 基线高危特征越多,绝对死亡获益越大。
核心结论
- 在慢性冠心病或外周动脉疾病患者中,利伐沙班联合阿司匹林较阿司匹林单药降低全因死亡和心血管死亡。
研究设计与样本
- COMPASS试验随机纳入18,278例患者,联合组9,152例,阿司匹林单药组9,126例,死亡由盲法委员会裁定。
主要发现
- 中位随访23个月(最长47个月),联合组死亡313例(3.4%),阿司匹林组378例(4.1%),HR 0.82(95%CI 0.71-0.96,P=0.01)。
- 心血管死亡联合组160例(1.7%),阿司匹林组203例(2.2%),HR 0.78(95%CI 0.64-0.96,P=0.02);非心血管死亡无差异。
- 基线高危特征为0、1、2、3或4个的患者,每1000例治疗30个月分别减少死亡4.2、4.8、25.0、53.9例。
临床怎么用
- 对慢性冠心病或外周动脉疾病患者,可评估利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次以降低死亡风险。
- 基线高危特征(多血管病变、慢性肾病、轻中度心衰、糖尿病)越多,绝对死亡获益越大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular (CV) events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). OBJECTIVES: The aim of this work was to report the effects of the combination on overall and cause-specific mortality. METHODS: The COMPASS trial enrolled 27,395 patients of whom 18,278 were randomized to the combination (n = 9,152) or aspirin alone (n = 9,126). Deaths were adjudicated by a committee blinded to treatment allocation. Previously identified high-risk baseline features were polyvascular disease, chronic kidney disease, mild or moderate heart failure, and diabetes. RESULTS: During a median of 23 months of follow-up (maximum 47 months), 313 patients (3.4%) allocated to the combination and 378 patients (4.1%) allocated to aspirin alone died (hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0.71-0.96; P = 0.01). Compared with aspirin, the combination reduced CV death (160 [1.7%] vs 203 [2.2%]; HR: 0.78; 95% CI: 0.64-0.96; P = 0.02) but not non-CV death. There were fewer deaths following MI, stroke, and CV procedures, as well as fewer sudden cardiac, other, and unknown causes of CV deaths and coronary heart disease deaths. Patients with 0, 1, 2, and 3 or 4 high-risk features at baseline had 4.2, 4.8, 25.0, and 53.9 fewer deaths, respectively, per 1000 patients treated for 30 months. CONCLUSIONS: The combination of rivaroxaban and aspirin compared with aspirin reduced overall and CV mortality with consistent reductions in cause specific CV mortality in patients with chronic CAD or PAD. The absolute mortality benefits are greater with increasing baseline risk. (Cardiovascular Outcomes for People Using Anticoagulant Strategies [COMPASS]; NCT01776424).
引用
- Eikelboom JW, Bhatt DL, Fox KAA, et al. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. J Am Coll Cardiol. 2021. PMID: 34210409. doi:10.1016/j.jacc.2021.04.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。